VINC — Vincerx Pharma Income Statement
0.000.00%
- $19.29m
- $14.18m
Annual income statement for Vincerx Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.001 | 0.173 | 62.7 | 71.2 | 42.6 |
Operating Profit | -0.001 | -0.173 | -62.7 | -71.2 | -42.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.001 | -0.119 | -39.3 | -63 | -40.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.001 | -0.12 | -39.3 | -63 | -40.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.001 | -0.12 | -39.3 | -63 | -40.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.001 | -0.12 | -39.3 | -63 | -40.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0 | -0.07 | -2.29 | -2.88 | -1.89 |
Dividends per Share |